Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.
Magarotto V et al. Blood. 2016 Jan 4. pii: blood-2015-08-662627. [Epub ahead of print].
Lenalidomide plus melphalan and prednisone, followed by lenalidomide maintenance versus thalidomide plus melphalan and prednisone, followed by thalidomide maintenance; results of the randomised phase 3 HOVON 87/NMSG18 trial.
Zweegman S et al. Blood. 2016 Jan 22. pii: blood-2015-11-679415. [Epub ahead of print].
Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance.
Cohen YC et al. Leuk Lymphoma. 2016 Jan 4:1-7. [Epub ahead of print].
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.
Afifi S et al. Bone Marrow Transplant. 2016 Jan 4. doi: 10.1038/bmt.2015.322. [Epub ahead of print].
Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation.
Landau H et al. Leuk Lymphoma. 2016 Jan 12:1-5. [Epub ahead of print].
Safe and prolonged survival with Long-term exposure to Pomalidomide in Relapsed/Refractory Myeloma.
Fouquet G et al. Ann Oncol. 2016 Jan 19. pii: mdw017. [Epub ahead of print].
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Totani H et al. Int J Hematol. 2015 Dec 29. [Epub ahead of print].
Bendamustine and dexamethasone are an effective salvage regimen for patients with advanced multiple myeloma in a Home Care Unit program.
Gentilini F et al. Leuk Lymphoma. 2015 Dec 23:1-3. [Epub ahead of print].